| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
|
Lancet
|
2012
|
3.29
|
|
2
|
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
|
J Acquir Immune Defic Syndr
|
2006
|
3.24
|
|
3
|
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
|
Lancet Infect Dis
|
2011
|
2.10
|
|
4
|
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients.
|
HIV Clin Trials
|
2007
|
1.97
|
|
5
|
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
|
J Infect Dis
|
2013
|
1.90
|
|
6
|
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
|
AIDS
|
2011
|
1.88
|
|
7
|
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
|
J Infect Dis
|
2004
|
1.80
|
|
8
|
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
|
J Infect Dis
|
2010
|
1.50
|
|
9
|
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
|
J Infect Dis
|
2004
|
1.37
|
|
10
|
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
|
J Acquir Immune Defic Syndr
|
2013
|
1.31
|
|
11
|
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
|
Antimicrob Agents Chemother
|
2004
|
1.16
|
|
12
|
The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.
|
HIV Clin Trials
|
2007
|
1.12
|
|
13
|
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
|
Antimicrob Agents Chemother
|
2005
|
1.07
|
|
14
|
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
|
J Acquir Immune Defic Syndr
|
2016
|
1.07
|
|
15
|
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
|
J Acquir Immune Defic Syndr
|
2007
|
1.06
|
|
16
|
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
|
Clin Pharmacokinet
|
2006
|
1.05
|
|
17
|
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
|
J Antimicrob Chemother
|
2014
|
0.94
|
|
18
|
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
|
Antivir Ther
|
2010
|
0.86
|
|
19
|
A Randomized , Open-label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Darunavir in Treatment-Experienced HIV-1 Infected Adults.
|
J Acquir Immune Defic Syndr
|
2016
|
0.83
|
|
20
|
A biofilm reactor-based approach for rapid on-line determination of biodegradable organic pollutants.
|
Biosens Bioelectron
|
2012
|
0.80
|
|
21
|
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
|
AIDS Patient Care STDS
|
2014
|
0.79
|
|
22
|
Graphene controlled H- and J-stacking of perylene dyes into highly stable supramolecular nanostructures for enhanced photocurrent generation.
|
Nanoscale
|
2014
|
0.77
|
|
23
|
Spontaneous and fast growth of large-area graphene nanofilms facilitated by oil/water interfaces.
|
Adv Mater
|
2012
|
0.77
|
|
24
|
Improvement in the assessment of direct and facilitated ion transfers by electrochemically induced redox transformations of common molecular probes.
|
Phys Chem Chem Phys
|
2012
|
0.75
|
|
25
|
Ion transfer voltammetry by a simple two polarized interfaces setup.
|
Anal Chem
|
2010
|
0.75
|
|
26
|
Which mechanism operates in the electron-transfer process at liquid/liquid interfaces?
|
Phys Chem Chem Phys
|
2010
|
0.75
|
|
27
|
Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients.
|
Liver Int
|
2009
|
0.75
|